The stock is driven by regulatory milestones, not quarterly earnings. The confirmed Q4 2026 NDA submission and pre-NDA meeting in Q3 2026 are the key catalysts. Monitor for any updates from the pre-NDA meeting and the interim SOL-R safety analysis in Q4 2026, which are required for the NDA package.
Price Chart
Executive Summary
Ocular Therapeutix reported Q2 2026 revenue of $13.5M (flat YoY) and a net loss of $(0.35) per share, which is a narrower loss than the $(0.39) in Q2 2025. The key catalyst is the confirmed FDA-aligned path to submit the AXPAXLI NDA for wet AMD in Q4 2026, with a pre-NDA meeting scheduled for Q3 2026. The stock will move on the regulatory clarity and the potential for a 2027 launch, not on the pre-revenue financials.
Key Financial Metrics
Key Facts
- AXPAXLI NDA submission for wet AMD on track for Q4 2026 following positive FDA Type C meeting.
- Pre-NDA meeting with FDA scheduled for Q3 2026; NDA to follow 505(b)(2) pathway, potentially accelerating review by up to 60 days.
- Total net revenue was $13.5M for Q2 2026, flat compared to Q2 2025.
- Net loss for Q2 2026 was $(78.8)M, or $(0.35) per share, vs. $(67.8)M, or $(0.39) per share in Q2 2025.
- Cash balance of $598.6M as of June 30, 2026, with expected runway into 2028.
- SOL-R trial amended to evaluate superiority vs. aflibercept (8 mg) at Week 96; topline results now expected in Q1 2028.
- HELIOS-3 trial streamlined to 620 patients evaluating once-yearly dosing (Q48W).
- Post-hoc analysis of SOL-1 shows up to 72% reduction in treatment burden vs. on-label aflibercept (2 mg).
Financial Impact
Pre-revenue biotech; $13.5M quarterly revenue from DEXTENZA is flat YoY. Cash burn of ~$78.8M per quarter. The value driver is the AXPAXLI NDA submission and potential approval, not current financials.
Risk Factors
- FDA may not accept the NDA for filing or may disagree with the 505(b)(2) pathway.
- SOL-R interim safety analysis or confirmatory evidence may be insufficient for the FDA.
- Commercial launch costs are not fully factored into the cash runway, potentially requiring future capital raises.
- SOL-R topline results delayed to Q1 2028, pushing out a potential label-expansion catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-089443 |
| Document: tm2621618d1_8k.htm | 0001104659-26-089443 |
| Document: 0001104659-26-089443-index-headers.html | 0001104659-26-089443 |
| Document: 0001104659-26-089443-index.html | 0001104659-26-089443 |
| Document: 0001104659-26-089443.txt | 0001104659-26-089443 |
| 8-K Data (Synthetic) | 0001104659-26-089443 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access